文献速递角膜与眼表疾病

感染性角膜炎管理进展

Update on the Management of Infectious Keratitis.
PubMed 文献 · Ophthalmology · 2017-09-21

感染性角膜炎是全球视力损害和失明的主要原因,常影响边缘化人群。培养仍是主要诊断工具,活体共聚焦显微镜有助于真菌和阿米巴诊断,下一代测序有望早期准确诊断难培养微生物。局部抗生素是细菌性角膜炎最佳治疗,但角膜融解、瘢痕和穿孔仍导致预后不良;辅助局部糖皮质激素在特定溃疡中似乎有益;真菌性溃疡预后较差,局部那他霉素优于伏立康唑,口服伏立康唑不推荐;病毒性角膜炎常复发,局部糖皮质激素和口服阿昔洛韦对基质型角膜炎有显著益处,口服阿昔洛韦使复发减少约一半。

要点

  • 局部抗生素是细菌性角膜炎最佳治疗,常用局部抗生素疗效相当。
  • 局部糖皮质激素对中央、深或大、非诺卡菌或典型侵袭性铜绿假单胞菌溃疡、低基线视力及早期使用似乎有益。
  • 局部那他霉素对真菌性溃疡优于局部伏立康唑,尤其镰刀菌属;口服伏立康唑不推荐。

核心结论

  • 未来减少感染性角膜炎相关发病率的策略可能是多维度的,以调节感染免疫反应的辅助治疗最有潜力改善临床结局。

研究设计与样本

  • 综述,总结感染性角膜炎诊断与治疗进展,包括培养、活体共聚焦显微镜、下一代测序及多项随机对照试验结果。

主要发现

  • 培养仍是主要诊断工具,活体共聚焦显微镜有助于诊断真菌和阿米巴,下一代测序有望早期准确诊断常规方法难培养的微生物。
  • 近期综述发现所有常用局部抗生素治疗细菌性角膜炎疗效相当,但角膜融解、瘢痕和穿孔仍导致预后不良。
  • 类固醇用于角膜溃疡试验发现局部糖皮质激素总体无显著改善,但对中央、深或大、非诺卡菌或典型侵袭性铜绿假单胞菌溃疡、低基线视力患者及抗生素开始后早期使用似乎有益。
  • 真菌性溃疡预后常差于细菌性溃疡,自1960年代局部那他霉素引入以来无新治疗;MUTT I显示局部那他霉素优于局部伏立康唑,尤其镰刀菌属溃疡;MUTT II显示口服伏立康唑总体未改善结局,镰刀菌属溃疡可能有一定效果,但非严重不良事件增加,作者结论不能推荐口服伏立康唑。
  • HEDS I显示局部糖皮质激素和口服阿昔洛韦对基质型角膜炎有显著益处;HEDS II显示口服阿昔洛韦使任何类型单纯疱疹病毒角膜炎复发减少约一半。

关键数值与推荐

  • 局部抗生素仍为细菌性角膜炎最佳治疗,近期综述发现所有常用局部抗生素疗效相当。
  • MUTT I显示局部那他霉素优于局部伏立康唑用于真菌性溃疡,尤其镰刀菌属。
  • MUTT II显示口服伏立康唑总体未改善结局,非严重不良事件增加,作者结论不能推荐口服伏立康唑。
  • HEDS II显示口服阿昔洛韦使任何类型单纯疱疹病毒角膜炎复发减少约一半。

临床怎么用

  • 细菌性角膜炎使用局部抗生素治疗。
  • 真菌性溃疡使用局部那他霉素治疗,尤其镰刀菌属。
  • 作者结论不能推荐口服伏立康唑用于真菌性溃疡。
  • 基质型角膜炎使用局部糖皮质激素和口服阿昔洛韦治疗。
  • 口服阿昔洛韦用于减少单纯疱疹病毒角膜炎复发。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infectious keratitis is a major global cause of visual impairment and blindness, often affecting marginalized populations. Proper diagnosis of the causative organism is critical, and although culture remains the prevailing diagnostic tool, newer techniques such as in vivo confocal microscopy are helpful for diagnosing fungus and Acanthamoeba. Next-generation sequencing holds the potential for early and accurate diagnosis even for organisms that are difficult to culture by conventional methods. Topical antibiotics remain the best treatment for bacterial keratitis, and a recent review found all commonly prescribed topical antibiotics to be equally effective. However, outcomes remain poor secondary to corneal melting, scarring, and perforation. Adjuvant therapies aimed at reducing the immune response associated with keratitis include topical corticosteroids. The large, randomized, controlled Steroids for Corneal Ulcers Trial found that although steroids provided no significant improvement overall, they did seem beneficial for ulcers that were central, deep or large, non-Nocardia, or classically invasive Pseudomonas aeruginosa; for patients with low baseline vision; and when started early after the initiation of antibiotics. Fungal ulcers often have worse clinical outcomes than bacterial ulcers, with no new treatments since the 1960s when topical natamycin was introduced. The randomized controlled Mycotic Ulcer Treatment Trial (MUTT) I showed a benefit of topical natamycin over topical voriconazole for fungal ulcers, particularly among those caused by Fusarium. MUTT II showed that oral voriconazole did not improve outcomes overall, although there may have been some effect among Fusarium ulcers. Given an increase in nonserious adverse events, the authors concluded that they could not recommend oral voriconazole. Viral keratitis differs from bacterial and fungal cases in that it is often recurrent and is common in developed countries. The Herpetic Eye Disease Study (HEDS) I showed a significant benefit of topical corticosteroids and oral acyclovir for stromal keratitis. HEDS II showed that oral acyclovir decreased the recurrence of any type of herpes simplex virus keratitis by approximately half. Future strategies to reduce the morbidity associated with infectious keratitis are likely to be multidimensional, with adjuvant therapies aimed at modifying the immune response to infection holding the greatest potential to improve clinical outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Austin A, Lietman T, Rose-Nussbaumer J, et al. Update on the Management of Infectious Keratitis. Ophthalmology. 2017. PMID: 28942073. doi:10.1016/j.ophtha.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。